Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TD139 in Healthy Volunteers and IPF Patients
NCT02257177Phase 2Completed
- Sponsor
- Galecto, Inc.
- Start
- Sep 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GB0139 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Galecto, Inc. Primary endpoint: Number of Participants With Adverse Events. Started Sep 2014; status: completed.
02
Drugs
GB0139
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02257177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257177.